Compare Mesoblast Limited (MESO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Raymond James Financial, Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Raymond James Financial, Inc. trades at $169.4 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is far larger — about 15.1× Mesoblast Limited's market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | RJF | |
|---|---|---|
Market Cap | $2.17B | $32.80B |
Sector | Technology | Financials |
52-Week High | $20.96 | $176.43 |
52-Week Low | $12.88 | $140.89 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Raymond James Financial (RJF) trades at $168.23, down slightly by 0.08% on the day. The stock shows a bullish technical trend with moving averages supporting upside momentum, while recent earnings beats and steady revenue growth highlight fundamental strength. Analyst consensus is positive with a $176.83 price target, and the company declared a $0.54 dividend payable in July 2026.
Outlook remains favorable given consistent earnings performance and strong analyst support, though rising expenses and market volatility pose risks. The stock's current valuation metrics, including a P/E of 15.9, suggest room for growth if execution continues. Key catalysts include upcoming Q2 2026 earnings and sustained advisor network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
